Acute renal insufficiency during telavancin therapy in clinical practice

    loading  Checking for direct PDF access through Ovid



To describe the tolerance to long-term telavancin therapy among inpatients as it relates to nephrotoxicity.


Retrospective cohort study of adult patients who received telavancin at the Barnes-Jewish Hospital from 1 September 2009 to 1 December 2010. Patients who received less than three doses of telavancin, were on haemodialysis prior to telavancin administration or died within 48 h of initial telavancin administration were excluded.


Twenty-one patients received telavancin and met the inclusion criteria. Seven of 21 patients (33%) developed acute renal insufficiency during therapy. Patients who developed acute renal insufficiency had a mean glomerular filtration rate reduction of 56 mL/min/1.73 m2. In the univariate analysis, high body mass index (P = 0.025), use of intravenous contrast dye (P = 0.017) and prior serum vancomycin trough levels >20 mg/L (P = 0.017) were associated with developing acute renal insufficiency. Two patients required haemodialysis; two had persistent renal insufficiency.


Supratherapeutic vancomycin trough levels, high body mass index and receipt of intravenous contrast dye prior to telavancin therapy were associated with acute renal insufficiency.

Related Topics

    loading  Loading Related Articles